Cargando…

“UniCAR”-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells

Antigen-specific redirection of immune effector cells with chimeric antigen receptors (CARs) demonstrated high therapeutic potential for targeting cancers of different origins. Beside CAR-T cells, natural killer (NK) cells represent promising alternative effectors that can be combined with CAR techn...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mitwasi, Nicola, Feldmann, Anja, Arndt, Claudia, Koristka, Stefanie, Berndt, Nicole, Jureczek, Justyna, Loureiro, Liliana R., Bergmann, Ralf, Máthé, Domokos, Hegedüs, Nikolett, Kovács, Tibor, Zhang, Congcong, Oberoi, Pranav, Jäger, Elke, Seliger, Barbara, Rössig, Claudia, Temme, Achim, Eitler, Jiri, Tonn, Torsten, Schmitz, Marc, Hassel, Jessica C., Jäger, Dirk, Wels, Winfried S., Bachmann, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7005792/ https://www.ncbi.nlm.nih.gov/pubmed/32034289 http://dx.doi.org/10.1038/s41598-020-59082-4

Ejemplares similares

UniCAR T cell immunotherapy enables efficient elimination of radioresistant cancer cells
por: Arndt, Claudia, et al.
Publicado: (2020)

Extended half-life target module for sustainable UniCAR T-cell treatment of STn-expressing cancers
por: Loureiro, Liliana R., et al.
Publicado: (2020)

Development of novel target modules for retargeting of UniCAR T cells to GD2 positive tumor cells
por: Mitwasi, Nicola, et al.
Publicado: (2017)

Highly Efficient Targeting of EGFR-Expressing Tumor Cells with UniCAR T Cells via Target Modules Based on Cetuximab(®)
por: Jureczek, Justyna, et al.
Publicado: (2020)

Targeting CD10 on B-Cell Leukemia Using the Universal CAR T-Cell Platform (UniCAR)
por: Mitwasi, Nicola, et al.
Publicado: (2022)

T cells engrafted with a UniCAR 28/z outperform UniCAR BB/z-transduced T cells in the face of regulatory T cell-mediated immunosuppression
por: Kegler, Alexandra, et al.
Publicado: (2019)

An oligo-His-tag of a targeting module does not influence its biodistribution and the retargeting capabilities of UniCAR T cells
por: Jureczek, Justyna, et al.
Publicado: (2019)

A theranostic PSMA ligand for PET imaging and retargeting of T cells expressing the universal chimeric antigen receptor UniCAR
por: Arndt, Claudia, et al.
Publicado: (2019)

Development of a novel target module redirecting UniCAR T cells to Sialyl Tn-expressing tumor cells
por: Loureiro, L. R., et al.
Publicado: (2018)

From mono- to bivalent: improving theranostic properties of target modules for redirection of UniCAR T cells against EGFR-expressing tumor cells in vitro and in vivo
por: Albert, Susann, et al.
Publicado: (2018)

Retargeting of UniCAR T cells with an in vivo synthesized target module directed against CD19 positive tumor cells
por: Bachmann, Dominik, et al.
Publicado: (2017)

Retargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology “UniCAR”
por: Feldmann, Anja, et al.
Publicado: (2017)

Evaluation of switch-mediated costimulation in trans on universal CAR-T cells (UniCAR) targeting CD123-positive AML
por: Meyer, Jan-Erik, et al.
Publicado: (2021)

Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity
por: Zhang, Congcong, et al.
Publicado: (2017)

Combining Radiation- with Immunotherapy in Prostate Cancer: Influence of Radiation on T Cells
por: Lindner, Diana, et al.
Publicado: (2022)

Development and Functional Characterization of a Versatile Radio-/Immunotheranostic Tool for Prostate Cancer Management
por: Arndt, Claudia, et al.
Publicado: (2022)

Multivalent adaptor proteins specifically target NK cells carrying a universal chimeric antigen receptor to ErbB2 (HER2)-expressing cancers
por: Pfeifer Serrahima, Jordi, et al.
Publicado: (2023)

Arming NK cells with enhanced antitumor activity: CARs and beyond
por: Oberoi, Pranav, et al.
Publicado: (2013)

Inability of granule polarization by NK cells defines tumor resistance and can be overcome by CAR or ADCC mediated targeting
por: Eitler, Jiri, et al.
Publicado: (2021)

Versatile chimeric antigen receptor platform for controllable and combinatorial T cell therapy
por: Feldmann, Anja, et al.
Publicado: (2020)

Conventional CARs versus modular CARs
por: Feldmann, Anja, et al.
Publicado: (2019)

Multimodal PET/MRI Imaging Results Enable Monitoring the Side Effects of Radiation Therapy
por: Kovács, Noémi, et al.
Publicado: (2018)

Targeting Acute Myeloid Leukemia Using the RevCAR Platform: A Programmable, Switchable and Combinatorial Strategy
por: Kittel-Boselli, Enrico, et al.
Publicado: (2021)

EGFR-Targeted Granzyme B Expressed in NK Cells Enhances Natural Cytotoxicity and Mediates Specific Killing of Tumor Cells
por: Oberoi, Pranav, et al.
Publicado: (2013)

Preclinical assessment of CAR-NK cell-mediated killing efficacy and pharmacokinetics in a rapid zebrafish xenograft model of metastatic breast cancer
por: Murali Shankar, Nivedha, et al.
Publicado: (2023)

Radiomic detection of microscopic tumorous lesions in small animal liver SPECT imaging
por: Veres, Dániel S., et al.
Publicado: (2019)

Maltose-Binding Protein Enhances Secretion of Recombinant Human Granzyme B Accompanied by In Vivo Processing of a Precursor MBP Fusion Protein
por: Dälken, Benjamin, et al.
Publicado: (2010)

Cytotoxic response of human regulatory T cells upon T-cell receptor-mediated activation: a matter of purity
por: Koristka, S, et al.
Publicado: (2014)

Validation of CD98hc as a Therapeutic Target for a Combination of Radiation and Immunotherapies in Head and Neck Squamous Cell Carcinoma
por: Köseer, Ayşe Sedef, et al.
Publicado: (2022)

Fluorescent, Prussian Blue-Based Biocompatible Nanoparticle System for Multimodal Imaging Contrast
por: Forgách, László, et al.
Publicado: (2020)

Synthesis and preclinical application of a Prussian blue-based dual fluorescent and magnetic contrast agent (CA)
por: Hegedűs, Nikolett, et al.
Publicado: (2022)

Correction: Synthesis and preclinical application of a Prussian blue-based dual fluorescent and magnetic contrast agent (CA)
por: Hegedűs, Nikolett, et al.
Publicado: (2023)

Etats-Unis : [guide /
Publicado: (1980)

Directed Differentiation of Mobilized Hematopoietic Stem and Progenitor Cells into Functional NK Cells with Enhanced Antitumor Activity
por: Oberoi, Pranav, et al.
Publicado: (2020)

Adaptor CAR Platforms—Next Generation of T Cell-Based Cancer Immunotherapy
por: Arndt, Claudia, et al.
Publicado: (2020)

Recommandations Etats-Unis
Publicado: (1994)

Royaume-Uni : Turbulences
Publicado: (1994)

CD19‐CAR engineered NK‐92 cells are sufficient to overcome NK cell resistance in B‐cell malignancies
por: Romanski, Annette, et al.
Publicado: (2016)

Intraperitoneal Glucose Transport to Micrometastasis: A Multimodal In Vivo Imaging Investigation in a Mouse Lymphoma Model
por: Ritter, Zsombor, et al.
Publicado: (2021)

Expression of Potential Targets for Cell-Based Therapies on Melanoma Cells
por: Strobel, Sophia B., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5d8h17a7he3cctvf3gh48f3usb